Two new compounds from rifamycin resistant mutant strain Streptomyces sp. HS-NF-1046R
10.16438/j.0513-4870.2018-0974
- VernacularTitle:利福霉素抗性突变菌Streptomyces sp. HS-NF-1046R中的两个新化合物
- Author:
Huan QI
1
,
2
;
Zheng MA
1
;
Zheng-lian XUE
3
;
Hai-ning RUAN
4
;
Mei-yue GAO
4
;
Hui ZHANG
4
;
Xiao-ping YU
1
;
Ji-dong WANG
2
,
3
Author Information
1. Zhejiang Provincial Key Laboratory of Biometrology and Inspection and Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China
2. Zhejiang Key Laboratory of Antifungal Drugs, Zhejiang Hisun Pharmaceutical Co., Ltd., Taizhou 318000, China
3. Microorganism Fermentation Engineering and Technology Research Center of Anhui Province, Institute of Biologic and Chemical Engineering of Anhui Polytechnic University, Wuhu 241000, China
4. Zhejiang Key Laboratory of Antifungal Drugs, Zhejiang Hisun Pharmaceutical Co., Ltd., Taizhou 318000, China
- Publication Type:Research Article
- Keywords:
italic>Streptomyces;
rifamycin resistant screening;
secondary metabolites;
structure elucidation
- From:
Acta Pharmaceutica Sinica
2019;54(1):117-121
- CountryChina
- Language:Chinese
-
Abstract:
Using silica gel column chromatography, gel chromatography and HPLC, we isolated secondary metabolites in fermentation broth of a rifamycin resistant mutation strain Streptomyces sp. HS-NF-1046R. Based on spectroscopic data, the chemical structures of three compounds were identified as 3-hydroxyl-2-N-propionyl- anthranilamide (1), 2,3-dihydro-8-hydroxy-2,2-dimethyl quinazolin-4-(1H)-one (2) and 2-aminobenzamide (3). Compounds 1 and 2, as new entities, were evaluated for cytotoxicity against A549, HepG2, HCT-116 and K562 cells using the SRB assay. Compounds 1 and 2 exhibited no cytotoxicity with IC50 over 100 μmol·L-1.
